The High Conviction 2026 model portfolio is built directly on our GoodStocks research — our ongoing series evaluating public companies on both shareholder return potential and net positive real-world impact. It brings together companies with top Ziggma Stock Scores, strong revenue and earnings growth, and measurable positive impact — a curated selection of businesses where we see the strongest potential for long-term compounding.
The High Conviction model portfolio returned +3.9% in June, bringing our year-to-date return to +32.9%. The S&P 500, by comparison, slipped about -1.1% in June and sits at -10.2% for the year. A solid win, in a month when the broader market got nervous about AI spending.
This portfolio carries a portfolio-level Ziggma Score of 95 — “Excellent” territory — with every holding rated “Strong” or better. We build it around real fundamentals, not whatever’s moving fastest that week, and June was a clear example of why: ABBV and LAUR posted double-digit gains, KEYS, MU, and STE shrugged off big news and ended flat, and our AI/growth names gave back ground as the market rotated away from anything AI-capex related. Price and business quality didn’t move together this month — but the earnings and revenue growth behind these companies, covered stock-by-stock below, kept building the long-term case regardless.
AbbVie had a strong June, climbing about 15% as the drugmaker raised its 2026 forecast and its top drugs, Skyrizi and Rinvoq, kept growing. The big news was a $10.9 billion deal to buy Apogee Therapeutics, moving AbbVie into new skin-condition treatments — analysts were split on whether the price was fair, though one raised its target afterward. The FDA also approved Skyrizi for kids with psoriasis. One thing to watch: lawmakers opened an inquiry into AbbVie’s clinical trials in China. Position is up about 13% since purchase.
Keysight had a genuinely strong earnings report — revenue grew 31% from a year ago, beating expectations, and the company raised its outlook. But the stock had already rallied hard beforehand, touching an all-time high, so it gave back most of those gains right after the report. Net result: the stock ended June almost exactly where it started, despite the business doing great. Position is still up over 50% since purchase. From the GoodStocks desk: Keysight’s testing tools help make electronics more efficient and lower-carbon, earning it a strong Impact Score of 83 — one reason we see it as a steady long-term compounder.
Laureate, our top-scoring stock, had a good June. The for-profit education company beat revenue expectations thanks to strong enrollment in Peru and Mexico, raised its earnings guidance, and bought back shares — pushing the stock up nearly 10% for the month. One thing to watch: LAUR was dropped from a few stock indexes in late June, which can reduce buying from index funds. Its next earnings report is due July 30. Position is up about 13% since purchase.
Mastercard’s June was about strategy as much as numbers. Revenue grew 12%, and the company is leaning more into higher-margin services beyond basic card payments. Two big wins: a court gave preliminary approval to settle Mastercard’s long-running legal dispute with merchants over card fees, and the company rolled out new tools using quantum computing to help fight fraud. Despite the good news, the stock is down about 7% since we bought it — a sign we paid a high price for a good company.
Microsoft had a rocky June. The stock fell about 17% as investors worried about how much money Big Tech is spending to build AI data centers — Microsoft’s own spending jumped 84% from a year ago. Still, the actual business kept performing well: Microsoft beat earnings expectations, and its cloud business (Azure) grew 40%. The company also held its big developer conference, showing off new AI tools across its products. This position is down about 20% since purchase, the portfolio’s weakest spot — but that reflects a pricey entry point, not a broken business. From the GoodStocks desk: We’ve asked whether Microsoft is the best long-term AI investment, for both returns and the climate, pointing to its pledge to be carbon-negative by 2030. This month’s dip doesn’t change that case.
Micron had the best quarter in the whole portfolio. Revenue and profit both crushed expectations, driven by huge demand for AI memory chips, and next quarter’s outlook was even stronger than analysts hoped. The stock jumped over 6% right after the report and briefly hit an all-time high. But a broader sell-off in chip stocks later in the month — partly triggered by Nvidia’s drop — erased those gains, leaving Micron roughly flat for June despite the record quarter. Position is up an incredible 232% since purchase, by far our biggest winner. From the GoodStocks desk: We called Micron the “AI memory backbone” poised for an earnings turnaround — a company recovering from a rough patch and still trading cheaply given its growth. June proved that thesis right, even if the stock price didn’t show it yet.
Nvidia fell about 8% in June, part of a broader pullback in AI and tech stocks — even though the business itself is firing on all cylinders. Revenue grew 85% from a year ago, driven by huge demand for AI chips. There was also a leadership change: a top sales executive left, replaced by someone poached from Microsoft. This position is only up modestly, about 3.5% since purchase, a small cushion given how strong the business has been.
Nextpower (formerly Nextracker) had a wild June. The solar-equipment company hit an all-time high in late May, then gave back a lot of those gains over the following weeks — even though the news was genuinely good. The company agreed to buy Prevalon Energy, a battery-storage business, for up to $365 million, pushing it beyond solar into energy storage and power for AI data centers. It also raised its revenue forecast for next year and got a late-month boost from analysts betting it would benefit if the U.S. bans Chinese-made solar equipment. Position is up about 25% since purchase. From the GoodStocks desk: Nextpower’s solar technology directly helps cut carbon emissions, earning it a strong Impact Score of 83. Its move into batteries and AI-related power only strengthens that story.
Insulet had a genuinely mixed June. The company rolled out an improved version of its Omnipod insulin device, but disclosed it would cost up to $50 million more than expected — sending the stock down over 7% on worries about execution. Still, the underlying business is strong: revenue grew 34% last quarter, and a company director bought about $500,000 of stock in early June, a vote of confidence. Position is down sharply, about 43% since purchase, our weakest holding — reflecting how expensive the stock was when we bought it. From the GoodStocks desk: We’ve featured PODD directly, and it’s actually a holding in Ziggma’s own model portfolio. Our take: this isn’t a safe, steady compounder — it’s what we call a “Path 2” stock, meaning higher risk but also higher potential upside. The idea is that Insulet’s stock price hasn’t caught up to how well the business, and its life-changing product, is actually doing. June’s swings are a good example of that gap in action.
Steris ended June almost exactly flat, but that hides a rough start followed by a real recovery in the back half of the month. The medical sterilization company posted record results for its fiscal year — revenue up nearly 9% and profit up over 27% — and announced a new $1 billion stock buyback. Its outlook for next year was seen as a bit conservative by some analysts. Position is down about 15% since purchase.
Looking ahead, we’ll watch for Laureate’s next earnings report on July 30, further movement on Nextpower’s Prevalon and Zimmermann deals, and whether the AI-capex anxiety that hit MSFT and NVDA in June starts to fade or gets worse. History says the price eventually catches up to the fundamentals.
__________________________________________________________________
Disclaimer
This information is provided solely for general information and educational use. It is not intended as, and should not be construed to be, financial, investment, tax, legal, or other professional advice. Data used in the analysis is derived from third-party sources and applicable at the time of publication of the analysis. No representation or warranty is made as to the accuracy or completeness of the information or any analysis herein.
Ziggma is not registered or licensed as a financial advisor, broker-dealer, or tax professional. Readers should perform their own independent research and seek advice from appropriately qualified professionals before making any financial, investment, or legal decisions.
You should presume that, as of the date this report is published or any related communication referencing publicly traded securities or assets, Ziggma team members may hold positions in the securities or assets discussed and could benefit financially from price movements. Positions may be changed without notice.
There is no duty to revise or update the content after publication. Neither Ziggma nor any affiliated parties accept responsibility for market changes, economic developments, or subsequent events that could affect the relevance or accuracy of the information.
Forward-Looking Statements
This report may include forward-looking statements, such as forecasts, projections, estimates, or expectations regarding financial outcomes, market dynamics, or future corporate developments. These statements are based on assumptions that may not hold true, and actual results may vary materially. The author undertakes no obligation to update or revise any forward-looking statements as circumstances change.
Third-Party Data & External Sources
Certain information is sourced from third parties. Nonetheless, the accuracy, completeness, and timeliness of such information cannot be assured. Ziggma disclaims any responsibility for errors or omissions in third-party data and does not endorse, verify, or assume accountability for the methodologies or conclusions of external sources.
AI-Generated Enhancements
AI tools can be used to enhance clarity, structure, and brevity, and to assist with research organization, ideation, and analytical review.
Redistribution
You may share this report for informational purposes. However, reproduction, distribution, republication, or modification of any portion of the content, in whole or in part, without prior written consent is prohibited.
Investment Risk Disclosure
All investing carries risk of loss.. Historical performance does not guarantee future outcomes. References to specific securities, companies, or strategies are for informational purposes only and do not constitute recommendations or endorsements. Any use of, or reliance on, the information in this report is entirely at the reader’s own risk.
Neither Ziggma nor affiliated parties shall be liable for any direct or indirect losses or damages of any kind arising from the use of this report or reliance on its contents. By accessing this report, you agree to indemnify and hold harmless Ziggma and affiliated parties from any claims, liabilities, or damages resulting from your use of the material.
You alone bear responsibility for your decisions. Use this information at your own discretion and risk.
